[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laguna Biotherapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100637009","phase-1-study-of-quail-100-in-pediatric-and-young-adult-participants-with-high-risk-hematologic-malignancies-who-have-received-a-hematopoietic-stem-cell-transplantation-100637009",false,"NCT07573111","Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation","An Open-label, First-in-Human, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Subjects With High-Risk Acute Leukemias and Myelodysplastic Syndrome Who Have Received a T-cell Receptor (TCR) αβ+ T Cell\u002FCD-19+ B Cell-Depleted Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Weight \\>\u002F= 10 kg\n* Have received HLA-partially matched related or unrelated donor ab-depleted hematopoietic stem cell transplant (HSCT) for high-risk malignant disease and has achieved myeloid and platelet engraftment\n* Lanksy\u002FKarnofsky score \\> 60\n* Participants of childbearing potential must agree to use contraception to prevent pregnancy\n\nExclusion Criteria:\n\n* Active Grade II acute graft versus host disease (aGVHD) requiring \\> 0.5 mg\u002Fkg methylprednisolone or any diagnosis of Grade III\u002FIV aGVHD\n* Significant cardiac, pulmonary, renal, hepatic, GI, neurological or immunological disease that could compromise safe participation\n* Known allergies, hypersensitivity or intolerance to both amoxicillin and gentamycin\n* Implanted medical devices with high potential for bacterial seeding, including pacemakers, artificial cardiac valves, prosthetic joints, orthopedic plates or screws, atrial appendage or inferior vena cava devices for thrombosis prevention\n* Planned anti-leukemic therapy within 21 days of planned dosing\n* Use of tumor necrosis factor (TNF) a or phosphatidylinositol 3-kinase (PI3K) inhibitors within 60 days of screening\n* Any prior investigational Listeria product including QUAIL-100\n* Live, attenuated vaccine within 4 weeks of first dose","ALL","18 Months","39 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant",[27,28],"Acute Leukemia","Myelodysplastic Syndrome",[30,31,32,33,34,35,36],"Leukemia","Myelodysplastic Syndrome (MDS)","Acute Lymphocytic Leukemia (ALL)","Acute Myeloid Leukemia (AML)","transplant","hematopoietic stem cell transplant","LGNA-100","NOT_YET_RECRUITING","2026-05-08",{"date":40,"type":41},"2026-05-13","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2029-03",{"name":47,"class":48},"Laguna Biotherapeutics, Inc.","INDUSTRY",""]